Virus Dataset Sample Info

> Dataset: 31248149 Search Result

Summary

Sample

ID	Sample ID	Age	Detail
1	120001	25	View
2	120018	20	View
3	120078	18	View
4	120176	24	View
5	120205	20	View
6	120253	37	View
7	120260	29	View
8	120314	37	View
9	120323	27	View
10	120325	30	View
11	120338	22	View
12	120466	26	View
13	120489	20	View
14	120499	18	View
15	120504	29	View
16	145008	24	View
17	145016	39	View
18	200079	27	View
19	200120	19	View
20	200125	24	View
21	200155	22	View
22	200178	31	View
23	200228	23	View
24	200246	18	View
25	200323	22	View
26	200342	24	View
27	200355	32	View
28	200368	18	View
29	200371	30	View
30	200427	31	View
31	200468	26	View
32	200489	22	View
33	200515	19	View
34	200533	24	View
35	200571	19	View
36	200575	18	View
37	200582	21	View

Literature

Item	Summary
PMID	31248149
Title	Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis.
Abstract	Intermittent use of a single antiretroviral agent in the presence of a replicating virus could potentially increase the development of antiviral resistance. The pericoital, before-and-after sex, dosing regimen used in the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 tenofovir gel trial meant that women who were infected with hepatitis B virus (HBV) were exposed intermittently to tenofovir during their participation. The impact of this dosing regimen on HBV resistance was assessed by amplification of the HBV polymerase region from 37 stored plasma samples of women who were HBV surface antigen positive. All samples belonged to HBV genotype A. None of the known tenofovir resistance mutations (M240V/I, L180M, A194T, V214A, N238T) were identified in any individuals. While it is reassuring that no resistance mutations were found among women using topical tenofovir, the rapidly expanding access to oral tenofovir-containing HIV pre-exposure prophylaxis (PrEP), with higher systemic exposure to the drug, makes monitoring for potential HBV drug resistance important.